![]()
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Applied brain injury research in New Zealand: can we
do better?
Valery L Feigin, Suzanne Barker-Collo
A search of Ovid MEDLINE (1950–2007), EMBASE
(1980–2007), Cochrane Central Register of Controlled Trials, and PsycINFO
(1806–2007) electronic databases for clinical research in stroke and
traumatic brain injury (TBI) yielded 48,208, 40,925, 6606, and 7133
publications, respectively (see Panel 1 for details on the search strategy).
Analysis of these publications in English-speaking countries (Panel 2) shows a
consistently high level of interest in applied brain injury research across the
countries identified.
Panel 1. Search strategy
![]() At this stage of our research and public health development
in New Zealand, it seems important to understand the extend of the problem of
brain injury in our country and to summarise and reflect upon existing gaps in
the research on brain injury epidemiology, treatment, and rehabilitation and how
these might be addressed in future research. Accounting for overlapping
publications between the electronic databases, results in a total of 210 New
Zealand originated publications in the field of stroke and 80 publications in
the field of TBI published since 1806.
Stroke and TBI are leading causes of morbidity, disability,
and mortality in New Zealand. Together they account for the second largest share
of total disability-adjusted life years lost and premature mortality in New
Zealand (8.5% and 11.7%, respectively), yielding priority to ischaemic heart
disease only.1
Each year in New Zealand, around 7000–8000 people
experience a stroke2 and 22,000–33,000
people experience a TBI.3 The costs to the
country are substantial, around NZ$219 to $253
Million2,3 in direct costs alone. Stroke and
TBI also contribute substantially to potentially preventable socioeconomic and
ethnic inequalities in New Zealand.2,4,5
Epidemiological studies are still needed to: explore the
causes of persisting ethnic disparities in stroke occurrence and outcomes in New
Zealand; the prevalence of and risk factors for TBI; lifetime risks of stroke
and TBI; predictors of various outcomes; and population awareness of these
disorders and their risk factors. It is important to maintain and further
advance the high standard of our stroke and TBI epidemiological studies as the
only reliable source of data for evidence-based health-care planning and
prevention that would contribute to reducing the impact of these devastating
disorders at individual and population levels.
Panel 2. Publications in applied stroke and
traumatic brain injury (TBI) research in the world (total and per 1 million
population) in selected countries by the source of electronic
database*
![]() *Totals are not always the exact sum of the components
because of the overlap in some publications between different electronic
databases.
While the number of publications in applied stroke and TBI
research in New Zealand and other countries are generally comparable, the number
and scope of randomised controlled trials (RCTs) in this critically important
area of research in our country and overseas are far from satisfactory. Over a
6-year period (1998–2003) there have been 13 registered, ongoing, or
completed RCTs in the field of stroke or injury (any injury) in New Zealand (A
Jull, personal communication, 2007).
Of the nine RCTs carried out in stroke/TBI patients in New
Zealand that were published and cited in MEDLINE until now (not accounting for
international multi-centre trials in which New Zealand centres were involved),
eight were in stroke patients6–13 and
only one was in TBI patients (a small trial evaluating effects of Tai Chi
Ghuan).14
Of the eight RCTs in stroke, five were drug-related
prevention or management trials7,8,10–12
and there were three small rehabilitation trials evaluating effects of gait
management,6 shoulder pain
prevention,9 and self-directed
exercises.13
Over half of stroke15 and
TBI16 survivors remain dependent on others for
everyday activities, often with significant adverse effects on informal (unpaid)
caregivers.17,18 Reducing the impact of stroke
and TBI on caregivers as well as patients is therefore key to the maintenance of
independence and quality of life for these groups with an associated reduction
in health service usage.
With a paucity of industry funded drug trials in New
Zealand, it is important to concentrate research on trialling practicable and
affordable approaches to rehabilitation of these most debilitating neurological
disorders. Rehabilitation efforts and expenditure have, to date, focused mainly
on motor/language functioning and activities of daily living. However, the
majority of stroke and TBI survivors experience ongoing disability, and the
impact of existing rehabilitation efforts is often limited.
Innovative rehabilitation interventions are urgently needed
to improve outcomes. For example, there is growing body of evidence to suggest
that one of the most promising ways to improve outcomes in stroke and TBI
survivors and their family caregivers would be to improve neuropsychological
impairment via cognitive and behavioural
interventions.19–23 There are, however,
gaps in quantifying, applying, utilising, and translating such knowledge into
policies and clinical and public health
practice.3,24,25 Should these interventions
prove to be effective, this may change the current practice of management of
brain injury.
It is vitally important to prioritise research on the basis
of their expected impact on the population health and make sure that those
interventions selected for evaluation are tested in properly designed and
executed clinical trials. In addition, interventions of proven effectiveness
(e.g. constraint-induced movement therapy in stroke
survivors)26 should be more widely used by
rehabilitation specialists.
New Zealand has several stroke and TBI experts and academics
of high national and international standing, strong traditions and expertise of
good quality epidemiological studies and clinical trials, and an elaborated
network of brain injury subject recruitment sites. However, many research groups
work in isolation, there is no cohesive stream of applied brain injury research
projects, workforce development and capacity building, especially within high
priority groups.
Currently in New Zealand a gap exists between basic and
applied neuroscience (e.g. a gap between identification and development of novel
treatment/rehabilitation interventions by basic neuroscientists and their
fast-track clinical testing by clinicians and clinical epidemiologists). To
address these issues, a coordinated and supported comprehensive and sustainable
brain injury research programme is urgently needed.
The experience of other developed countries indicates that
the development and implementation of such a programme is best accomplished via
specialised multidisciplinary research centres consisting of clinicians, public
health physicians, clinical epidemiologists and basic neuroscientists (including
experts in stroke, TBI, neurorehabilitation, and neuropsychology).
Recently the Health Research Council, Ministry of Health,
and Accident Compensation Corporation (ACC) have announced strategic objectives
and priority portfolios to encourage initiatives in the field of impairment,
rehabilitation, and disability. However, practical realisation of these
initiatives is a challenging multidimensional task that requires coordinated
efforts of academicians (e.g. universities), government institutions (e.g.
Ministry of Health, ACC), research charity organisations, and healthcare policy
makers.
Whether we are ready to accept the challenge and further
advance brain injury research in New Zealand to the benefits of our people
remains to be seen.
Competing interests: None known.
Author information: Valery L Feigin,
Associate Professor and Senior Research Fellow, Clinical Trials Research Unit,
School of Population Health, Faculty of Health & Medical Sciences; Suzanne
Barker-Collo, Senior Lecturer, Department of Psychology, Faculty of Science; The
University of Auckland, , Auckland
Correspondence: Associate Professor Valery
L Feigin, Clinical Trials Research Unit, School of Population Health, Faculty of
Health & Medical Sciences, The University of Auckland, Private Bag 92019,
Auckland, New Zealand. Fax: +64 (0)9 3737510; email: v.feigin@ctru.auckland.ac.nz
References:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Current
issue | Search journal |
Archived issues | Classifieds
| Hotline (free ads) Subscribe | Contribute | Advertise | Contact Us | Copyright | Other Journals |